You searched for
Category:
#Corporate
Bringing Sustainability and Strategy together to create Shared Value: Insights from Chiesi’s 2023 Sustainability Report
22/07/2024
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
06/05/2024
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices
22/04/2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
05/03/2024
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07/07/2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12/04/2023
Restore to Impact - The next healthcare landmark for innovation and future-oriented competencies
01/03/2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27/01/2023
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
17/01/2023
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
08/01/2023
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
04/12/2022
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
21/11/2022
Chiesi announces the departure of Ugo Di Francesco as CEO of the Group
31/08/2022
Chiesi Group continues to grow
31/03/2022
Chiesi France receives Choose France’s “Contribution au plan de relance (Contribution to Stimulus Plan)” special award from the Minister for Territorial Cohesion and Relations with Local Authorities
19/01/2022